Niquitin Minilozenge (Nicotine)

Nicotine, the active ingredient in Niquitin Minilozenge, is a nicotine replacement therapy presented as a lozenge for oromucosal use. It helps adult smokers who want to quit by reducing withdrawal symptoms and cravings. The product is intended for use under the guidance of a healthcare professional as part of a comprehensive cessation program.

GNH USA supplies Niquitin Minilozenge as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Niquitin Minilozenge, a nicotine replacement therapy, is used to aid smoking cessation by addressing nicotine dependence. - Smoking cessation: assists adult smokers in quitting by alleviating cravings and withdrawal symptoms. - Relapse prevention: supports individuals who have quit to maintain abstinence and avoid relapse. - Nicotine dependence: provides a controlled nicotine source to reduce the physiological drive for tobacco use.

Niquitin Minilozenge may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Mouth irritation or soreness: mild discomfort in the oral cavity. - Hiccups: brief, involuntary diaphragmatic contractions. - Nausea or upset stomach: occasional digestive upset. - Increased salivation: excess saliva production. - Throat irritation: scratchy feeling in the throat.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Chest pain or palpitations: unusual cardiac sensations. - Severe mouth ulceration: persistent ulcer that does not heal. - Anaphylaxis: rare, life‑threatening systemic allergic response. - Arrhythmia: irregular heart rhythm requiring medical attention.

Before using Niquitin Minilozenge, consider the following safety measures. - Assess nicotine dependence: evaluate the level of tobacco use to select appropriate therapy. - Medical guidance: use under the supervision of a qualified healthcare professional. - Contraindication: avoid if known hypersensitivity to nicotine or any excipients. - Cardiovascular caution: use with care in patients with recent heart disease or uncontrolled hypertension. - Not for non‑smokers: avoid use in individuals who do not use tobacco products. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Niquitin Minilozenge can interact with other substances that affect nicotine metabolism or cardiovascular function.

Major Interactions (Avoid): - Concurrent nicotine products: using other nicotine replacement therapies or tobacco can lead to excess nicotine exposure. - Monoamine oxidase inhibitors (MAOIs): may increase the risk of hypertensive episodes.

Moderate Interactions (Monitor Closely): - Caffeine: nicotine may enhance stimulant effects, leading to jitteriness. - Warfarin: nicotine can alter anticoagulant control; monitor INR. - Antipsychotics (e.g., clozapine): nicotine may affect plasma levels; adjust dosing if needed. - Beta‑blockers: nicotine may increase heart rate, requiring closer cardiovascular monitoring.